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Abstract
Objective: We studied whether the change in antibiotic susceptibility testing (AST) guidelines from CLSI to EUCAST
influenced cumulative antibiograms in a tertiary care hospital in Switzerland.
Methods: Antibiotic susceptibilities of non-duplicate isolates collected within a one-year period before (period A) and
after (period B) changing AST interpretation from CLSI 2009 to EUCAST 1.3 (2011) guidelines were analysed. In
addition, period B isolates were reinterpreted according to the CLSI 2009, CLSI 2013 and EUCAST 3.1 (2013)
guidelines.
Results: The majority of species/drug combinations showed no differences in susceptibility rates comparing periods
A and B. However, in some gram-negative bacilli, decreased susceptibility rates were observed when comparing
CLSI 2009 with EUCAST 1.3 within period B: Escherichia coli / cefepime, 95.8% (CLSI 2009) vs. 93.1% (EUCAST
1.3), P=0.005; Enterobacter cloacae / cefepime, 97.0 (CLSI 2009) vs. 90.5% (EUCAST 1.3), P=0.012; Pseudomonas
aeruginosa / meropenem, 88.1% (CLSI 2009) vs. 78.3% (EUCAST 1.3), P=0.002. These differences were still
evident when comparing susceptibility rates according to the CLSI 2013 guideline with EUCAST 3.1 guideline. For P.
aeruginosa and imipenem, a trend towards a lower antibiotic susceptibility rate in ICUs compared to general wards
turned into a significant difference after the change to EUCAST: 87.9% vs. 79.8%, P=0.08 (CLSI 2009) and 86.3%
vs. 76.8%, P=0.048 (EUCAST 1.3).
Conclusions: The change of AST guidelines from CLSI to EUCAST led to a clinically relevant decrease of
susceptibility rates in cumulative antibiograms for defined species/drug combinations, particularly in those with
considerable differences in clinical susceptibility breakpoints between the two guidelines.
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Introduction
The European Committee for Antimicrobial Susceptibility
Testing (EUCAST) was initiated to harmonize minimum
inhibitory concentration (MIC) breakpoints across Europe [1]. In
line with many European clinical laboratories, the University of
Zurich’s Institute of Medical Microbiology, Switzerland,
changed its antibiotic susceptibility testing (AST) system from
the Clinical and Laboratory Standards Institute (CLSI) 2009
methodology to the EUCAST 1.3 AST guidelines on 1st July
2011 [2,3].
In general, EUCAST recommends lower resistance MIC
breakpoints than CLSI, in particular for Gram-negative bacteria,
and, in part, abandoned the intermediate susceptibility zone.
These changes have been shown to result in different
susceptibility rates, e.g. higher cefepime and meropenem
resistance rates in Pseudomonas aeruginosa [4], higher
ceftazidime and ceftriaxone resistance rates in Escherichia coli
causing bacteremia [5], higher ceftazidime resistance in ESBL-
producing E. coli and Klebsiella pneumonia [6], and higher
cefepime and ceftazidime resistance in ESBL producing E. coli
[7]. However, the actual effect of the guideline changes on
cumulative hospital antibiograms is unknown, even though
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local cumulative antibiograms are important for guiding
empirical antibiotic therapy [8,9], and changes in cumulative
resistance rates may influence the choice of empirical
antimicrobial treatment [10].
This study was designed to determine whether and to which
extent susceptibility rates in cumulative antibiograms of the five
most prevalent bacterial species in our tertiary-care hospital
would differ between two consecutive years before and after
changing from CLSI 2009 to EUCAST 1.3 (2011) AST
guidelines. Furthermore, we determined whether differences in
cumulative antibiograms represented true changes in
antimicrobial susceptibility, or if they were merely an effect of
guideline changes.
In addition, as resistance rates of cumulative antibiograms
from general ward specimens reportedly differ from those
found on intensive care units (ICUs), we aimed to determine
whether guideline dependent changes differed between ICUs
and general wards [11,12].
Materials and Methods
Setting
The University Hospital Zurich, Zurich, Switzerland, is an 871
bed tertiary-care teaching hospital covering all medical
specialties except paediatrics and orthopaedics. Six intensive
care units (medical ICU, general, thoracic and transplant
surgery ICU, trauma ICU, burn ICU, cardiac surgery ICU,
neurosurgery ICU) with a total of 65 beds are assigned to
different departments. Hematopoietic stem cell transplantations
are performed in a specialized unit. All microbiologic samples
are tested in the clinical microbiology laboratory of the Institute
of Medical Microbiology, University of Zurich, Zurich,
Switzerland.
Data collection
Data were collected in two consecutive one-year periods just
before (period A) and after (period B) the change of AST
interpretation from CLSI 2009 to EUCAST 1.3 on 1 July 2011.
All bacterial isolates from samples collected on general wards
and intensive care units were taken into account. In addition,
samples of the outpatients’ clinic for respiratory medicine were
included in a subgroup analysis for P. aeruginosa.
The species analysed comprised E. coli, K. pneumoniae,
Enterobacter cloacae, P. aeruginosa, and Staphylococcus
aureus. According to the guidelines for analysis and
presentation of cumulative antibiograms, we excluded all
repeated isolates, i.e. only the first isolate of a certain
bacterium per patient and year was analysed, regardless of the
material, the donor site, or the resistance profile [13].
In addition, isolates collected on the general wards and on
the ICUs were analysed separately. The “ICU section”
consisted of the six ICUs and the hematopoietic stem cell
transplantation unit. The “ward-section” consisted of all general
wards.
Susceptibility testing
For susceptibility testing, the disc diffusion method according
to Kirby-Bauer was used [14]. Antibiotic discs were obtained
from i2a (Montpellier, France). Susceptibility testing was done
on Mueller-Hinton agar (Becton-Dickinson, Franklin Lakes, NJ,
USA) using MacFarland 0.5 from overnight cultures followed by
incubation at 35°C for 16-18h. Inhibition zone diameters were
determined and recorded in the automated Sirweb/Sirscan
system (i2a) and interpreted according to CLSI 2009 and
EUCAST 1.3 guidelines [2,3].
Comparison of CLSI 2009 and EUCAST 1.3 (2011)
For certain drugs, e.g. ceftazidime, cefotaxime, and
piperacillin/tazobactam, EUCAST guidelines contain other
antibiotic disc loads than CLSI guidelines, preventing a direct
comparison of disk diffusion AST results [2,3]. Thus, we only
included drugs into analysis that have identical antibiotic disc
loads in both CLSI and EUCAST guidelines, i.e., amoxicillin/
clavulanic acid, cefuroxime, cefoxitin, ceftriaxone, cefepime,
imipenem, meropenem, tobramycin, sulfomethoxazole/
trimethoprim, ciprofloxacin, gentamicin, erythromycin,
clindamycin, rifampin, and teicoplanin.
The first one-year period (period A) was interpreted
according to CLSI 2009 guidelines only. Period B was originally
interpreted according to EUCAST 1.3 guidelines. In order to
analyze whether or not changes in susceptibility rates over time
were due to the guideline change alone, results of period B
were reinterpreted according to CLSI 2009 guidelines.
Additionally, period B was reinterpreted according to CLSI
2013 and EUCAST 3.1.
Isolates of intermediate susceptibility were classified together
with resistant isolates to the “non-susceptible”-group.
Statistical analyses
Differences in group proportions were assessed using chi-
square or Fisher’s exact tests, as appropriate. We used Stata
(Version 12.1, StataCorp, College Station, Texas) for statistical




Between July 2010 and June 2011 (period A), 2540 isolates
(1085 E. coli, 277 K. pneumoniae, 186 E. cloacae, 271 P.
aeruginosa, 721 S. aureus) were included. Between July 2011
and June 2012 (period B), 2688 isolates (1177 E. coli, 310 K.
pneumoniae, 200 E. cloacae, 282 P. aeruginosa, 719 S.
aureus) were included.
Four different “patterns” of effects on susceptibility rates
were found when comparing the cumulative antibiograms of
period A and period B by either interpreting the antibiograms
according to CLSI 2009 or according to EUCAST 1.3 AST
guidelines (Figure 1).
Pattern 1 - Artificial changes in susceptibility rates.  A
decrease in the cefepime susceptibility rates of E. coli and E.
cloacae from period A to period B was observed (Table 1,
CLSI vs EUCAST Antibiotic Susceptibility Cut-Offs
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comparison 1). These differences disappeared when periods A
and B were both interpreted according to CLSI 2009 AST
guidelines (Table 1, comparison 2).
Pattern 2 - Competing effects.  When comparing P.
aeruginosa / meropenem susceptibility rates defined according
to CLSI 2009 guidelines in both periods, more specimens were
reported susceptible in period B than in period A (Table 1,
comparison 2), reflecting a true epidemiological change. When
period A was analysed according to CLSI 2009 and period B
according to EUCAST 1.3 AST guidelines, the reported
susceptibility rates did not differ (Table 1, comparison 1). A
similar effect was shown for P. aeruginosa / imipenem and
ciprofloxacin susceptibility rates.
Pattern 3 - Cumulative effects.  Amoxicillin/clavulanic acid
susceptibility rates of E. coli and K. pneumonia increased
between period A and B when both periods were interpreted
according to CLSI 2009 AST guidelines (Table 1, comparison
2). This increase was amplified by interpreting period B
according to EUCAST 1.3 AST guidelines (Table 1,
comparison 3).
Pattern 4 - True changes in susceptibility rates.  E. coli
ceftriaxone susceptibility and K. pneumoniae tobramycin
susceptibility rates increased from period A to period B, while
Figure 1.  Different patterns of effects and distributions of inhibition zone diameters.  Part A: Different “patterns of effects”
when analysing period A according CLSI 2009 guidelines and period B according CLSI 2009 and EUCAST 1.3 guidelines; numbers
are percent susceptible. Part B: Distribution of inhibition zone diameters of E.coli and cefepime: isolates of columns in black are not
classified as “susceptible” any more when reported according to EUCAST 1.3 guidelines. Part C: Distribution of inhibition zone
diameters of E. coli and meropenem: no change of susceptibility rate when EUCAST 1.3 guidelines are applied. Part D: Distribution
of inhibition zone diameters of E. coli and amoxicillin/clavulanic acid: overlap of wild-type and resistent bacteria, leading to a change
in classification from “intermediate” to “susceptible” (black column) of a near significant number of isolates when EUCAST 1.3
guidelines are applied.
doi: 10.1371/journal.pone.0079130.g001
CLSI vs EUCAST Antibiotic Susceptibility Cut-Offs
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cefoxitin susceptibility rates of S. aureus decreased (Table 1,
comparison 1). These changes in susceptibility rates remained
when CLSI 2009 guidelines were applied to period B (Table 1,
comparison 2).
Table 1. Comparison of cumulative antibiograms of two adjacent one-year periods by either applying CLSI or EUCAST
guidelines.
  Comparison 1 Comparison 2 Comparison 3 Comparison 4
  CLSI 2009
EUCAST
1.3 (2011)  CLSI 2009 CLSI 2009  CLSI 2009
EUCAST
1.3 (2011)  CLSI 2013
EUCAST
3.1 (2013)  
Species Drug PeriodAa Period B











E.coli Amoxicillin/clavulanic acid 81.3 87.9 <0.001 81.3 85.3 0.011 85.3 87.9 0.07 85.3 87.9 0.07
 Cefuroxime 89.6 90.9 0.32 89.6 90.9 0.32 90.9 90.9 1.00 90.9 90.9 1.00
 Ceftriaxone 87.8 92.5 0.001 87.8 92.7 <0.001 92.7 92.5 0.94 92.5 92.5 1.00
 Cefepime 97.1 93.1 <0.001 97.1 95.8 0.11 95.8 93.1 0.005 95.8 93.1 0.005
 Imipenem 100.0 100.0 n.a. 100.0 100.0 n.a. 100.0 100.0 n.a. 100.0 100.0 n.a.
 Meropenem 100.0 100.0 n.a. 100.0 100.0 n.a. 100.0 100.0 n.a. 100.0 100.0 n.a.
 Tobramycin 88.1 88.8 0.70 88.1 89.7 0.34 89.7 88.8 0.51 89.7 88.6 0.43
 Sulfomethoxazole/trimethoprim 68.6 65.2 0.08 68.6 65.2 0.08 65.2 65.2 1.00 65.2 65.2 1.00




clavulanic acid 85.6 92.3 0.011 85.6 89.7 0.13 89.7 92.3 0.33 89.7 92.3 0.33
 Cefuroxime 87.0 89.6 0.37 87.0 89.6 0.37 89.6 89.6 n.a. 89.6 89.6 1.00
 Ceftriaxone 88.6 91.6 0.28 88.6 91.6 0.28 91.6 91.6 1.00 91.6 91.6 1.00
 Cefepime 96.0 92.6 0.08 96.0 95.5 0.84 95.5 92.6 0.17 95.5 92.6 0.17
 Imipenem 98.9 99.4 0.67 98.9 99.4 0.67 99.4 99.4 1.00 98.4 99.0 0.72
 Meropenem 98.0 99.0 0.44 98.0 99.4 0.22 99.4 99.0 1.00 98.7 99.0 1.00
 Tobramycin 87.1 93.9 0.010 87.1 94.2 0.006 94.2 93.9 1.00 94.2 93.2 0.74
 Sulfomethoxazole/trimethoprim 81.2 81.3 1.00 81.2 81.3 1 81.3 81.3 1.00 81.3 81.3 1.00
 Ciprofloxacin 88.8 93.5 0.06 88.8 93.9 0.037 93.9 93.5 1.00 93.9 93.5 1.00
E. cloacae Amoxicillin/clavulanic acid 4.8 9.0 0.12 4.8 7.5 0.30 7.5 9.0 0.72 7.5 9.0 0.72
 Cefuroxime 66.5 70.5 0.44 66.5 70.5 0.44 70.5 70.5 1.00 70.5 70.5 1.00
 Ceftriaxone 73.8 74.5 0.90 73.8 76.0 0.63 76.0 74.5 0.82 74.5 74.5 1.00
 Cefepime 97.3 90.5 0.006 97.3 97.0 1.00 97.0 90.5 0.012 97.0 90.5 0.012
 Imipenem 100.0 99.5 1.00 100.0 100.0 n.a. 100.0 99.5 1.00 95.0 98.5 0.09
 Meropenem 100.0 97.5 0.07 100.0 100.0 n.a. 100.0 97.5 0.06 97.0 97.5 0.77
 Tobramycin 95.7 96.0 1.00 95.7 96.0 1.00 96.0 96.0 1.00 96.0 96.0 1.00
 Sulfomethoxazole/trimethoprim 93.0 91.0 0.57 93.0 91.0 0.57 91.0 91.0 1.00 91.0 91.0 1.00
 Ciprofloxacin 95.1 96.0 0.81 95.1 96.5 0.61 96.5 96.0 1.00 96.5 96.0 1.00
P. aeruginosa Cefepime 85.6 88.7 0.31 85.6 88.7 0.31 88.7 88.7 1.00 88.7 88.7 1.00
 Imipenem 76.7 82.9 0.07 76.7 85.1 0.013 85.1 82.9 0.57 83.3 82.9 1.00
 Meropenem 79.7 78.3 0.74 79.7 88.1 0.013 88.1 78.3 0.002 86.3 78.3 0.015
 Tobramycin 91.6 94.6 0.21 91.6 94.6 0.21 94.6 94.6 1.00 94.6 94.6 1.00
 Ciprofloxacin 84.1 90.7 0.021 84.1 93.9 <0.001 93.9 90.7 0.20 93.9 90.7 0.20
S. aureus Cefoxitin 96.7 94.4 0.041 96.7 94.4 0.041 94.4 94.4 1.00 94.4 94.4 1.00
 Gentamicin 98.2 98.7 0.52 98.2 98.9 0.38 98.9 98.7 1.00 98.9 98.7 1.00
 Sulfomethoxazole/trimethoprim 99.2 99.3 1.00 99.2 99.3 1.00 99.3 99.3 1.00 99.3 99.3 1.00
 Erythromycin 87.2 87.8 0.74 87.2 86.9 0.87 86.9 87.8 0.63 86.9 87.8 0.63
 Clindamycin 97.6 98.4 0.33 97.6 98.4 0.33 98.4 98.4 1.00 98.4 98.4 1.00
 Rifampicin 99.4 98.6 0.18 99.4 98.7 0.27 98.7 98.6 1.00 98.7 98.6 1.00
 Teicoplanin 100.0 100.0 n.a. 100.0 100.0 n.a. 100.0 100.0 n.a. 100.0 100.0 n.a.
CLSI vs EUCAST Antibiotic Susceptibility Cut-Offs
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Table 1 shows that, besides changing AST patterns
described above, there was no difference in susceptibility rates
between the two periods in the majority of isolates, neither
when comparing CLSI 2009 AST guidelines applied to period A
and EUCAST 1.3 guidelines to period B (comparison 1), nor
when periods A and B were both interpreted according to CLSI
2009 AST guidelines (comparison 2). The results of
comparison 3 were unchanged when inhibition zone diameters
of period B interpreted according to CLSI 2103 and EUCAST
3.1 were compared (comparison 4).
Comparison of cumulative antibiograms of intensive
care units, general wards and other units
Regardless of the methodology applied, susceptibility rates
of E. coli to cefuroxime, ceftriaxone and cefepime, and
susceptibility rates of S. aureus to clindamycin were lower in
cumulative antibiograms of intensive care units as compared to
those of general wards (Table 2). Similarly, a trend to lower
susceptibility rates in ICUs could be detected in some other
species/drug combinations.
For P. aeruginosa and imipenem, a trend towards a lower
antibiotic susceptibility rate in ICUs compared to general wards
turned into a significant difference after the change to EUCAST
1.3 (Table 2). Moreover, in P. aeruginosa isolates collected in
the outpatients’ clinic for respiratory medicine, which include
specimens of numerous patients with cystic fibrosis and lung
transplant recipients, a decrease in ciprofloxacin susceptibility
rate was notable when applying EUCAST 1.3, but not CLSI
2009 guidelines (data not shown).
Discussion
This observational study was designed to analyse cumulative
hospital antibiograms in two adjacent one-year periods before
and after the clinical laboratory changed antibiotic susceptibility
test interpretation from CLSI 2009 to EUCAST 1.3 (2011)
guidelines, and to analyse whether possible differences are
due to true epidemiologic changes or result only from CLSI /
EUCAST guideline differences. Differences resulting from
guideline changes alone may misdirect physicians in the
interpretation of antibiotic susceptibility trends in that truly
increasing resistance rates may be missed or unchanging
resistance rates may be reported as increasing or decreasing,
resulting in a change of antibiotic use patterns and thus patient
management and quality of care.
Clinical breakpoint (CBP) setting is a multi-step process
comprising the determination of epidemiological cut off
(ECOFF) values from MIC distributions, correlating these
ECOFFs to zone diameters distributions, comparing putative
CBPs to available PK/PD data and, finally, clinical validation of
putative CBPs in clinical outcome studies [15].
CLSI and EUCAST use different methods for the
determination of disc diffusion CBPs: CLSI uses a variant of
the error-rate-bounded method, sometimes incorporating an
intermediate zone [16], and EUCAST first defines MIC
breakpoints on the basis of epidemiological MIC cut-offs
(ECOFFs) and pharmacokinetic/pharmacodynamic (PK/PD)
parameters, and correlates those MIC CBPs to zone diameter
values using the “MIC-coloured zone diameter histogram
technique” [17,18]. The EUCAST policy of CBP setting
promises more transparency in this still complex, rather
consensus based process as all documents on diameter/MIC
distributions, and ECOFF data are publicly available [19].
Such different CBP determination methods inevitably lead to
different CBPs in CLSI and EUCAST AST guidelines for many
species/drug combinations. EUCAST 1.3 (generally unchanged
in EUCAST 2.0 and 3.1) disk diffusion CBPs are frequently
higher as compared to CLSI 2009, and in many cases even
higher as compared to revised CLSI guideline versions 2010 to
2013 [2,3,20-24]. Several studies have shown a significant
impact of guideline changes on the reporting of AST results
[4-7].
Instead of a uniform trend towards lower reported
susceptibility rates for all species/drug combinations after
implementation of EUCAST guidelines, this study showed four
distinct patterns of effects of guidelines changes on
susceptibility rates: i) a clearly artificial change of susceptibility
rates due to changes in AST guidelines (e.g. E. coli / cefepime
and E. cloacae / cefepime; Table 1, comparison 3); ii)
competing effects of artificial changes in susceptibility rates
and true epidemiologic variations (e.g. P. aeruginosa /
meropenem; Table 1, comparisons 2 and 3); iii) cumulative
effects resulting from artificial changes enhancing a true
epidemiologic variation (e.g. E. coli/amoxicillin and clavulanic
acid; Table 1, comparisons 2 and 3) and iv) a true change of
susceptibility rates due to epidemiologic variation (e.g. E. coli /
ceftriaxone; Table 1, comparison 2).
Three species/drug combinations (E. coli / cefepime, E.
cloacae / cefepime and P. aeruginosa / meropenem) showed a
statistically significant, yet artificial, decrease in susceptibility
rates when period B was analysed according to EUCAST 1.3
(2011) instead of CLSI 2009 guidelines. For these three
species/drug combinations, susceptible clinical inhibition zone
diameter breakpoints differ substantially between EUCAST 1.3
and CLSI 2009 guidelines, i.e., 6 mm difference for cefepime
susceptible CBP and Enterobacteriaceae (susceptible CPB
CLSI 2009 18 mm; EUCAST 1.3 24 mm), and 8 mm difference
in meropenem CBP for P. aeruginosa (susceptible CPB CLSI
2009 16 mm; EUCAST 1.3 24 mm).
Table 1 (continued).
a1 July 2010 to 30 June 2011, numbers are percent susceptible
b1 July 2011 to 30 June 2012, numbers are percent susceptible
n.a. not applicable.
doi: 10.1371/journal.pone.0079130.t001
CLSI vs EUCAST Antibiotic Susceptibility Cut-Offs
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Table 2. Comparison of cumulative antibiograms of wards
vs. ICUs by either applying CLSI 2009 or EUCAST 1.3
(2011) guidelines to period Ba.
  CLSI 2009  EUCAST 1.3 (2011)
Species Drug WardsICUs P-value WardsICUs
P-
value
E. coli Amoxicillin/clavulanic acid 85.9 82.4 0.20  88.4 85.7 0.29
 Cefuroxime 92.1 85.1 0.003  92.1 85.1 0.003
 Ceftriaxone 93.5 89.0 0.039  93.3 89.0 0.043
 Cefepime 96.6 92.4 0.012  94.2 88.2 0.004
 Imipenem 100 100 n.a.  100 100 n.a.
 Meropenem 100 100 n.a.  100 100 n.a.
 Tobramycin 90.5 86.2 0.08  89.5 85.2 0.07
 Sulfomethoxazole/trimethoprim 65.0 65.9 0.87  65.0 65.9 0.87




clavulanic acid 89.9 89.3 0.84  92.5 91.7 0.81
 Cefuroxime 89.3 90.5 0.84  89.3 90.5 0.84
 Ceftriaxone 91.2 92.9 0.82  91.2 92.9 0.82
 Cefepime 95.1 96.4 0.77  92.5 92.9 1.00
 Imipenem 99.6 98.8 0.47  99.6 98.8 0.47
 Meropenem 99.6 98.8 0.47  99.1 98.8 1.00
 Tobramycin 94.7 92.9 0.59  94.2 92.9 0.60
 Sulfomethoxazole/trimethoprim 79.6 85.7 0.25  79.6 85.7 0.25
 Ciprofloxacin 93.4 95.2 0.79  93.4 94.0 1.00
E. cloacae Amoxicillin/clavulanic acid 7.6 7.4 1.00  9.8 7.4 0.79
 Cefuroxime 72.0 67.6 0.62  72.0 67.6 0.62
 Ceftriaxone 77.3 73.5 0.60  75.8 72.1 0.61
 Cefepime 96.2 98.5 0.67  90.9 89.7 0.80
 Imipenem 100 100 n.a.  99.2 100 1.00
 Meropenem 100 100 n.a.  97.0 98.5 0.66
 Tobramycin 94.7 98.5 0.27  94.7 98.5 0.27
 Sulfomethoxazole/trimethoprim 88.6 95.6 0.12  88.6 95.6 0.12
 Ciprofloxacin 96.2 97.1 1.00  95.4 97.1 0.72
P.
aeruginosa Cefepime 88.0 89.9 0.70  88.0 89.9 0.70
 Imipenem 87.9 79.8 0.08  86.3 76.8 0.048
 Meropenem 90.5 83.8 0.12  80.8 73.7 0.18
 Tobramycin 95.0 93.9 0.78  95.0 93.9 0.78
 Ciprofloxacin 93.3 94.9 0.79  90.6 90.9 1.00
S. aureus Cefoxitin 94.1 95.2 0.72  94.1 95.2 0.72
 Gentamicin 98.8 99.0 1.00  98.6 99.0 1.00
 Sulfomethoxazole/trimethoprim 99.0 100 0.33  99.0 100 0.33
 Erythromycin 86.4 87.9 0.63  87.5 88.4 0.80
 Clindamycin 99.2 96.6 0.02  99.2 96.6 0.02
 Rifampicin 98.6 99.0 1.00  98.4 99.0 0.73
 Teicoplanin 100 100 n.a.  100 100 n.a.
a1 July 2011 to 30 June 2012, numbers are percent susceptible
n.a. not applicable.
doi: 10.1371/journal.pone.0079130.t002
The present study showed significant changes in
susceptibility rates for individual species/drug combinations
with substantial differences in susceptible CBPs between both
former and current CLSI and EUCAST guidelines. The
probability and extent of changes, however, both depend on
the inhibition zone diameters distributions of individual species/
drug combinations and, thus, depend on the epidemiological
situation present. This is seen in E. coli and meropenem,
where a 6 mm difference between CBPs does not lead to
changes in susceptibility rates (Figure 1b and c).
Most important, some species/drug combinations, for which
wild-type and resistant population zone diameters are not
clearly separated, may be affected by only minor CBP
changes, e.g. E. coli and amoxicillin/clavulanic acid (Figure 1d),
for which a susceptible CBP difference of 1 mm (susceptible
CBP CLSI 2009 18 mm; EUCAST 1.3 17 mm) led to an almost
significant increase in susceptibility rates from 85.3% to 87.9%
(Table 1, Comparison 3).
Empirical antibiotic treatment is not only guided by individual
patient characteristics, but also by epidemiological data such
as local susceptibility rates [9]. Usually, empirical antibiotic
treatment of specific pathogens or specific infections is
recommended only if a certain level of resistance is not
exceeded. Examples are the empirical treatment of cystitis with
a threshold of 80% susceptible isolates for any antibiotic agent
[25], or community acquired pneumonia and macrolide-therapy
with a threshold of 75% susceptible isolates [26].
Consequently, changes in reported susceptibility rates will
influence empirical antibiotic therapy. Meropenem susceptibility
of P. aeruginosa dropped from 88.1% to 78.3% when analyzed
according to CLSI 2009 and EUCAST 1.3 guidelines. This
significant decrease in the meropenem susceptibility rate by
EUCAST interpretation may, therefore, have a practical impact
on the choice of the empirical antibiotic therapy in patients with
life-threatening infections, and could result in more toxic (e.g.
aminoglycosides, colistin) or less effective antibiotic regimens.
The results of this study are in concordance with those of
other authors demonstrating that susceptibility rates differ
between ICU’s and general wards [11,27]. Corresponding
differences were observed for cephalosporin susceptibility
rates of E. coli, and clindamycin susceptibility rates of S.
aureus when applying both CLSI and EUCAST guidelines.
However, for imipenem susceptibility rates of P. aeruginosa, a
significant difference between ICU’s and general wards was
found only if applying EUCAST 2011, but not with CLSI 2009
(Table 2). Moreover, ciprofloxacin susceptibility rates of
P.aeruginosa isolates collected in the outpatient clinic for
respiratory medicine decreased significantly when EUCAST
2011 guidelines were applied. The most likely reason is a
different inhibition zone diameter distribution (i.e. a shift
towards lower inhibition zone diameters) of isolates originating
from this patient population, resulting in a comparably stronger
effect of guideline changes on susceptibility rates. These two
examples show that guideline changes can affect different
hospital wards to a different extent.
Thus, effects of AST guidelines are not easily predictable
and are dependent on the epidemiological situation. Both
clinicians and microbiologists should, therefore, know their
CLSI vs EUCAST Antibiotic Susceptibility Cut-Offs
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local epidemiology to be able to foresee effects of AST
guideline changes on clinical practice. In addition, switching
guidelines should be accompanied by thorough analyses
during one time period where both guidelines are applied in
order to detect bacteria/drug combinations belonging to one of
the patterns described here. This might be particularly
important in settings with higher resistance rates.
Despite a broad general set of data, the smaller sample size
for the general ward/ICU distinction may have obscured
significant differences in this study. In addition, this study is
limited to the epidemiological situation in one single institution
in north-eastern Switzerland, which is a low prevalence region
for antibiotic resistance, hampering generalizability to other
geographic settings. Effects of CBP changes as shown in this
work may, thus, differ from the situation in high-prevalence
regions.
In conclusion, this study demonstrates that changes in AST
guidelines, e.g. from CLSI 2009 to EUCAST 1.3 (2011)
guidelines, can influence a hospital’s cumulative antibiogram in
various ways. These changes cannot be easily predicted and
may differ between hospital units. Even cautious interpretation
can only serve as an approximation of the real epidemiological
changes. Nevertheless, these issues have to be taken into
account when interpreting cumulative antibiograms in a period
after significant AST guideline changes. Further studies are
needed to assess the effect of the guideline changes on
different local epidemiological situations.
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